{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T05:07:08Z","timestamp":1770354428152,"version":"3.49.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[1998,7,1]],"date-time":"1998-07-01T00:00:00Z","timestamp":899251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Pathology"],"published-print":{"date-parts":[[1998,7]]},"DOI":"10.1016\/s0002-9440(10)65540-x","type":"journal-article","created":{"date-parts":[[2011,1,28]],"date-time":"2011-01-28T05:02:45Z","timestamp":1296190965000},"page":"17-23","source":"Crossref","is-referenced-by-count":418,"title":["Macrophages in Human Atheroma Contain PPAR\u03b3"],"prefix":"10.1016","volume":"153","author":[{"given":"Nikolaus","family":"Marx","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galina","family":"Sukhova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curran","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Libby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Plutzky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/S0002-9440(10)65540-X_bib1","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/00041433-199610000-00012","article-title":"Macrophages and atherosclerotic plaque stability","volume":"7","author":"Libby","year":"1996","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/S0002-9440(10)65540-X_bib2","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1161\/01.RES.77.5.863","article-title":"Matrix metalloproteinases and cardiovascular disease","volume":"77","author":"Dollery","year":"1995","journal-title":"Circ Res"},{"key":"10.1016\/S0002-9440(10)65540-X_bib3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/hrt.69.5.377","article-title":"Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cells content","volume":"69","author":"Davies","year":"1993","journal-title":"Br Heart J"},{"key":"10.1016\/S0002-9440(10)65540-X_bib4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0021-9150(91)90235-U","article-title":"Atherosclerotic plaque caps are locally weakened when macrophages density is increased","volume":"87","author":"Lendon","year":"1991","journal-title":"Atherosclerosis"},{"key":"10.1016\/S0002-9440(10)65540-X_bib5","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1161\/01.CIR.92.6.1393","article-title":"Interstitial collagenase (MMP-1) expression in human carotid atherosclerotics","volume":"92","author":"Nikkari","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/S0002-9440(10)65540-X_bib6","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1172\/JCI117619","article-title":"Increased expression of matrix metalloproteinases and matrix degradation activity in vulnerable regions of human atherosclerotic plaques","volume":"94","author":"Galis","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/S0002-9440(10)65540-X_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4049\/jimmunol.156.1.1","article-title":"Matrix metalloproteinases in immunity","volume":"156","author":"Goetzl","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/S0002-9440(10)65540-X_bib8","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1172\/JCI114867","article-title":"Neutral metalloproteinases produced by human mononuclear phagocytes: enzyme profile, regulation, and expression during cellular development","volume":"86","author":"Welgus","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1016\/S0002-9440(10)65540-X_bib9","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.4049\/jimmunol.157.9.4159","article-title":"TNF-\u03b1 and IL-1\u03b2 selectively induce expression of 92-kd gelatinase by human macrophages","volume":"157","author":"Saren","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/S0002-9440(10)65540-X_bib10","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/01.RES.81.3.448","article-title":"Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes","volume":"81","author":"Schoenbeck","year":"1997","journal-title":"Circ Res"},{"key":"10.1016\/S0002-9440(10)65540-X_bib11","first-page":"197","article-title":"Nuclear hormone receptors inhibit matrix metalloproteinases (MMP) gene expression through diverse mechanisms","volume":"6","author":"Schroen","year":"1996","journal-title":"Gene Exp"},{"key":"10.1016\/S0002-9440(10)65540-X_bib12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/00041433-199706000-00006","article-title":"Peroxisome proliferator-activated receptors, orphans with ligands and functions","volume":"8","author":"Schoonjans","year":"1997","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/S0002-9440(10)65540-X_bib13","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1172\/JCI119424","article-title":"Peroxisome proliferator-activated receptor gene expression in human tissues: effects of obesity, weight loss, and regulation by insulin and glucocorticoids","volume":"99","author":"Vidal-Puig","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/S0002-9440(10)65540-X_bib14","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/0092-8674(94)90006-X","article-title":"Stimulation of adipogenesis in fibroblasts by PPAR \u03b32, a lipid-activated transcription factor","volume":"79","author":"Tontonoz","year":"1994","journal-title":"Cell"},{"key":"10.1016\/S0002-9440(10)65540-X_bib15","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1101\/gad.10.8.974","article-title":"Differential activation of adipogenesis by multiple PPAR isoforms","volume":"10","author":"Brun","year":"1996","journal-title":"Genes Dev"},{"key":"10.1016\/S0002-9440(10)65540-X_bib16","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/0092-8674(95)90199-X","article-title":"The nuclear receptor superfamily: the second decade","volume":"83","author":"Mangelsdorf","year":"1995","journal-title":"Cell"},{"key":"10.1016\/S0002-9440(10)65540-X_bib17","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/0092-8674(95)90193-0","article-title":"M. 15-Deoxy-delta 12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR \u03b3","volume":"83","author":"Forman","year":"1995","journal-title":"Cell"},{"key":"10.1016\/S0002-9440(10)65540-X_bib18","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/0092-8674(95)90194-9","article-title":"A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor \u03b3 and promotes adipocyte differentiation","volume":"83","author":"Kliewer","year":"1995","journal-title":"Cell"},{"key":"10.1016\/S0002-9440(10)65540-X_bib19","doi-asserted-by":"crossref","first-page":"23975","DOI":"10.1074\/jbc.270.41.23975","article-title":"Differential activation of peroxisome proliferator-activated receptors by eicosanoids","volume":"270","author":"Yu","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/S0002-9440(10)65540-X_bib20","doi-asserted-by":"crossref","first-page":"12953","DOI":"10.1074\/jbc.270.22.12953","article-title":"An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor \u03b3","volume":"270","author":"Lehmann","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/S0002-9440(10)65540-X_bib21","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1021\/jm950395a","article-title":"The structure-activity relationship between peroxisome proliferator-activated receptor \u03b3 agonism and the antihyperglycemic activity of thiazolidinediones","volume":"39","author":"Willson","year":"1996","journal-title":"J Med Chem"},{"key":"10.1016\/S0002-9440(10)65540-X_bib22","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1073\/pnas.94.9.4318","article-title":"Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors \u03b1 and \u03b3","volume":"94","author":"Kliewer","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S0002-9440(10)65540-X_bib23","first-page":"281","article-title":"Isolation of the human peroxisome proliferator activated receptor \u03b3 cDNA: expression in hematopoietic cells and chromosomal mapping","volume":"4","author":"Greene","year":"1995","journal-title":"Gene Expression"},{"key":"10.1016\/S0002-9440(10)65540-X_bib24","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/35154","article-title":"PPAR-\u03b3 agonists inhibit production of monocyte inflammatory cytokines","volume":"391","author":"Jiang","year":"1998","journal-title":"Nature"},{"key":"10.1016\/S0002-9440(10)65540-X_bib25","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/34178","article-title":"The peroxisome proliferator-activated receptor-\u03b3 is a negative regulator of macrophage activation","volume":"391","author":"Ricote","year":"1998","journal-title":"Nature"},{"key":"10.1016\/S0002-9440(10)65540-X_bib26","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/362801a0","article-title":"The pathogenesis of atherosclerosis: a perspective for the 1990s","volume":"362","author":"Ross","year":"1993","journal-title":"Nature"},{"key":"10.1016\/S0002-9440(10)65540-X_bib27","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1749-6632.1997.tb51991.x","article-title":"Is overamplification of the normal macrophage defensive role critical to lesion development?","volume":"811","author":"Raines","year":"1997","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/S0002-9440(10)65540-X_bib28","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1073\/pnas.92.2.402","article-title":"Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases","volume":"92","author":"Galis","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S0002-9440(10)65540-X_bib29","doi-asserted-by":"crossref","first-page":"8154","DOI":"10.1073\/pnas.88.18.8154","article-title":"Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization","volume":"88","author":"Henney","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S0002-9440(10)65540-X_bib30","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1096\/fasebj.9.10.7615167","article-title":"Microscopic localization of active proteases by in situ zymography: detection of matrix metalloproteinase activity in vascular tissue","volume":"9","author":"Galis","year":"1995","journal-title":"FASEB J"},{"key":"10.1016\/S0002-9440(10)65540-X_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0952-3278(92)90178-L","article-title":"Biological activities and mechanisms of action of PGJ2 and related compounds: an update","volume":"47","author":"Fukushima","year":"1992","journal-title":"Prostaglandins Leukotrienes Essent Fatty Acids"},{"key":"10.1016\/S0002-9440(10)65540-X_bib32","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0090-6980(88)90093-7","article-title":"The biology and pharmacology of PGD2","volume":"35","author":"Giles","year":"1988","journal-title":"Prostaglandins"},{"key":"10.1016\/S0002-9440(10)65540-X_bib33","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.4049\/jimmunol.143.9.2982","article-title":"The major source of endogenous prostaglandin D2 is likely antigen-presenting cells","volume":"143","author":"Urade","year":"1989","journal-title":"J Immunol"},{"key":"10.1016\/S0002-9440(10)65540-X_bib34","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1056\/NEJM199411033311803","article-title":"Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone","volume":"331","author":"Nolen","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/S0002-9440(10)65540-X_bib36","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJM199803263381302","article-title":"Effect of troglitazone in insulin-treated patients with type II diabetes mellitus","volume":"338","author":"Schwartz","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/S0002-9440(10)65540-X_bib35","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJM199803263381303","article-title":"Efficacy and metabolic effects of merformin and troglitazone in type II diabetes mellitus","volume":"338","author":"Inzucchi","year":"1998","journal-title":"N Engl J Med"}],"container-title":["The American Journal of Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000294401065540X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000294401065540X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:30:09Z","timestamp":1685925009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000294401065540X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,7]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1998,7]]}},"alternative-id":["S000294401065540X"],"URL":"https:\/\/doi.org\/10.1016\/s0002-9440(10)65540-x","relation":{},"ISSN":["0002-9440"],"issn-type":[{"value":"0002-9440","type":"print"}],"subject":[],"published":{"date-parts":[[1998,7]]}}}